$740M deal ends COVID-19 vaccine feud between CureVac and BioNTech

Payout and licensing deal grants US rights to COVID-19 and flu products | Agreement paves way for BioNTech’s $1.25 billion acquisition of CureVac.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Abbott unit defends European protection for heart valve ‘cuff’ design

19 February 2026 An EPO appeals board has denied Boston Scientific’s bid to revoke St Jude Medical’s transcatheter aortic valve replacement (TAVR) patent, but declined to hand a complete victory to the patent owner.

Americas

Natera targets ex-employee over mass file download before rival move

19 February 2026 The genetic testing firm claims that a former oncology specialist stole hundreds of confidential files in the dead of night, days before moving to a competitor.

Americas

New rankings recognise top US patent firms and lawyers

13 February 2026 This year’s featured firms and individuals ranked by sister title WIPR, include those instructed on the biggest tech and life sciences cases, as well as the strategists devising global AI patent portfolios.

More features

Abbott unit defends European protection for heart valve ‘cuff’ design

Natera targets ex-employee over mass file download before rival move

Hogan Lovells makes senior public and administrative hire in Italy

Danaher moves to acquire Masimo in $9.9bn deal

Generic rival blocked as AZ defends diabetes stronghold

Emotional Perception exclusive: ‘We are now very much open for business’

New rankings recognise top US patent firms and lawyers

Norton Rose Fulbright expands pharma and biotech disputes team

$740M deal ends COVID-19 vaccine feud between CureVac and BioNTech

More on this story

Editor's picks

Editor's picks

More features